Knight therapeutics announces filing of new drug submission for crexont® (carbidopa and levodopa) extended-release capsules in canada

Montreal, july 18, 2025 (globe newswire) -- knight therapeutics inc., (tsx: gud) ("knight") a pan-american (ex-usa) specialty pharmaceutical company, announced today that knight's new drug submission (nds) for crexont® has been accepted for review by health canada.

AMRX Ratings Summary

AMRX Quant Ranking